INDIANAPOLIS, May 16, 2016 /PRNewswire/ -- Chip Ganassi Racing Teams (CGRT) and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500.
Novo Nordisk Chip Ganassi Racing will change the number of Kimball's Tresiba® Chevrolet from its usual No. 83 to No. 42 at the 2016 Indianapolis 500. He will borrow the number from fellow CGRT teammate, Kyle Larson, driver of the No. 42 Target Chevrolet SS in the NASCAR Sprint Cup Series (NSCS). Larson has a cousin living with diabetes, so the program has a personal tie for him. Larson's No. 42 NSCS car will carry Kimball's name on it for the Coca-Cola 600 race weekend, also running on May 29, to honor those living with diabetes.
The number 42 is a reference to the duration of action of Tresiba®, a once-daily, long-acting basal insulin approved for blood sugar control in adults with diabetes, which was launched by Novo Nordisk earlier this year. Tresiba® lasts at least 42 hours after eight once-daily injections (0.4 U/kg). Patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Patients must ensure that at least eight hours have elapsed between Tresiba® injections.
Kimball was diagnosed with type 1 diabetes in 2007, and in addition to sporting the logo on his car, takes Tresiba®, along with a mealtime insulin, as part of his daily diabetes management.
As part of the efforts to raise diabetes awareness at the Indianapolis 500, Kimball's No. 42 Tresiba® Chevrolet will carry the name of 42 leaders in the diabetes community. Included among the names on the car are Dominique Wilkins, Billie Jean King, diabetes organizations such as JDRF, and first all-diabetes professional cycling team, Team Novo Nordisk. Additionally, Novo Nordisk will make a $4,200 donation to the Indiana Chapter of the American Diabetes Association (ADA) on behalf of the Verizon IndyCar Series driver who is leading the race after the 42nd lap of the Indianapolis 500. Novo Nordisk will also make the same $4,200 donation to the Charlotte Chapter of the ADA on behalf of the NSCS driver who leads the Coke 600 after lap 42.
The 2016 race season marks the eighth consecutive year of partnership between Novo Nordisk and Kimball and the sixth year of partnership between Kimball, Novo Nordisk and CGRT. Since his type 1 diabetes diagnosis, Kimball has been a passionate diabetes advocate. He is the face of Novo Nordisk's award-winning Race with Insulin® campaign, which aims to raise awareness and educate the public about diabetes management.
For the remainder of the 2016 Verizon IndyCar Series campaign, Kimball will run his normal car number, No. 83.
Charlie Kimball, No. 42 Tresiba® Chevrolet (Verizon IndyCar Series)
"The 100th running of the Indianapolis 500 will be the highlight of this year's season and it gives me a great opportunity to honor the diabetes community and help inspire those people living with or affected by diabetes. As a race car driver and a person living with diabetes, the duration of action of Tresiba® is important to me and plays an important role in my management plan. I am honored to represent Novo Nordisk and Chip Ganassi Racing and to share my story with the diabetes community."
Kyle Larson, No. 42 Target Chevrolet (NSCS)
"All of us who race for Chip (Ganassi) really are one team and it's really cool to share the No. 42 with Charlie, especially for this historic race. He is a strong and popular advocate for the diabetes community and I can't wait to see him and the No. 42 in this year's Indianapolis 500."
Chip Ganassi, Team Owner, Chip Ganassi Racing Teams
"It's been great to see Novo Nordisk use their racing partnership with Chip Ganassi Racing Teams to launch one of their brands, and I love that we're strengthening our 'one team' mantra with the sharing of the number 42 across different series. The number 83 is obviously very meaningful to both Charlie and myself, but the number 42 is also just as meaningful with this product and the diabetes community. Charlie had a great run last year at the 500, so hopefully the 42 will bring Novo Nordisk Chip Ganassi Racing and Charlie their first Indianapolis 500 victory."
Camille Lee, Senior Vice President, Diabetes & Obesity Marketing, Novo Nordisk Inc.
"As an individual living with diabetes, Charlie continues to be such an inspiration and leader for the community of others affected by diabetes. By changing the number of the Tresiba® Chevrolet to 42, and displaying names of real people touched by the disease on his car for this historic race, he is making great strides to honor the diabetes community."
What is Tresiba®?
- Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults with diabetes
- Tresiba® is not for people with diabetic ketoacidosis
- Tresiba® is available in 2 concentrations: 200 units/mL and 100 units/mL
- It is not known if Tresiba® is safe and effective in children under 18 years of age
Important Safety Information
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Who should not take Tresiba®?
Do not take Tresiba® if you:
- are having an episode of low blood sugar
- are allergic to Tresiba® or any of the ingredients in Tresiba®
Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
- pregnant, planning to become pregnant, or are breastfeeding
- taking new prescription or over-the-counter medicines, vitamins, or herbal supplements
Talk to your health care provider about low blood sugar and how to manage it.
How should I take Tresiba®?
- Read the Instructions for Use and take Tresiba® exactly as your health care provider tells you to
- Do not do any conversion of your dose. The dose counter always shows the selected dose in units
- Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to
- If you miss or are delayed in taking your dose of Tresiba®:
- Take your dose as soon as you remember, then continue with your regular dosing schedule
- Make sure there are at least 8 hours between doses
- Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them
- Do not reuse or share your needles with other people. You may give them a serious infection, or get a serious infection from them
- Never inject Tresiba® into a vein or muscle
- Never use a syringe to remove Tresiba® from the FlexTouch® pen
What should I avoid while taking Tresiba®?
- Do not drive or operate heavy machinery, until you know how Tresiba® affects you
- Do not drink alcohol or use prescription or over-the-counter medicines that contain alcohol
What are the possible side effects of Tresiba®?
Tresiba® may cause serious side effects that can be life-threatening, including:
- Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache
- Low potassium in your blood (hypokalemia)
- Heart failure in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Tresiba®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Common side effects may include reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please click here for Prescribing Information.
Tresiba® is a long-acting insulin that lasts at least 42 hours after the last of eight once-daily injections (0.4 U/kg), and has a consistently flat and stable profile at steady state.1-3 Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® should take their dose as soon as they remember, then continue with their regular dosing schedule, making sure there are at least eight hours between doses.1 Tresiba® is available in Novo Nordisk's latest insulin delivery device – FlexTouch® – as a 100 units/mL or 200 units/mL pen. Tresiba® U-200 FlexTouch® can dose up to 160 units in a single injection.1 FlexTouch® is also the only prefilled insulin pen with no push-button extension.1
In the United States, more than 29 million people are affected by diabetes.4 Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.4 Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has almost quadrupled over the past 30 years.5
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has more than 5,000 employees in the United States. For more information, visit novonordisk-us.com or follow us on Twitter: @novonordiskus.
About Chip Ganassi Racing Teams
Chip Ganassi has been a fixture in the auto racing industry for over 25 years and is considered one of the most successful, as well as innovative, owners the sport has anywhere in the world. Today his teams include four cars in the Verizon IndyCar Series, two cars in the NASCAR Sprint Cup Series, one car in the NASCAR XFINITY Series, two factory Ford GTs in the IMSA WeatherTech SportsCar Championship, two factory Ford GTs in the FIA World Endurance Championship and two Supercars in Red Bull Global Rallycross. Overall his teams have 18 championships and 170 victories, including four Indianapolis 500s, a Daytona 500, a Brickyard 400, six Rolex 24 at Daytonas and the 12 Hours of Sebring. Ganassi boasts state-of-the-art race shop facilities in Indianapolis and Concord, N.C., with a corporate office in Pittsburgh, Penn. For more information, log on to: www.chipganassiracing.com.
- Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2015.
- Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Diabetes Obes Metab. 2012;14(9):859-864.
- Heise T, Korsatko S, Nosek L, et al. J Diabetes. 2016;8(1):132-138.
- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. CDC website. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed April 19, 2016.
- Centers for Disease Control and Prevention. Number (in Millions) of Civilian, Noninstitutionalized Adults with Diagnosed Diabetes, United States, 1980–2014. CDC website. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed April 19, 2016.
FlexTouch®, Race with Insulin®, and Tresiba® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2016 Novo Nordisk All rights reserved. USA16TSM01210 May 2016
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novo-nordisk-chip-ganassi-racing-teams-and-charlie-kimball-honor-the-diabetes-community-with-the-no-42-tresiba-insulin-degludec-injection-200-unitsml-chevrolet-at-the-100th-running-of-the-indianapolis-500-300268959.html
SOURCE Novo Nordisk